

REVIEW

Open Access



Is allergic sensitization relevant in severe asthma? Which allergens may be culprits?

Carlo Lombardi^{1*}, Eleonora Savi², Erminia Ridolo³, Giovanni Passalacqua⁴ and Giorgio Walter Canonica⁴

Abstract

Severe asthma is a major health concern. The allergic (IgE-mediated) form of asthma is well known from a pathogenic viewpoint. We searched the available literature to identify which allergens are most frequently associated with severe, refractory or life threatening asthma. According to the results, molds, pet dander, cockroach and ragweed were more frequently responsible for severe asthma. Thunderstorm asthma, in addition, represents a special association between allergic sensitization and an external climatic factor. A detailed knowledge of the most harmful allergens is mandatory for an appropriate diagnostic and preventive approach.

Keywords: Severe asthma, Atopy, Allergic sensitization, Allergens

Background

Bronchial asthma, which prevalence is around 5-10% worldwide [1, 2], remains a major health problem in all age groups for patients, their families and the community. The asthma-related respiratory symptoms cause a limitation of everyday activity with consequent absenteeism/presenteism. Exacerbations may require extra visits, emergency room admissions, and hospitalizations. Of note, fatalities continue to be reported [3]. Indeed, in the majority of patients, asthma can be adequately treated with the standard of care therapy [4], and most patients achieve a satisfactory control of the disease. Nonetheless, a not negligible subgroup of subjects remains “difficult-to-treat” or “uncontrolled” despite adequate therapy. “Severe” or “difficult to treat” or “refractory” asthma is a heterogeneous condition that encompasses different phenotypes/endotypes, such as eosinophilic, obesity-related, neutrophilic, late onset asthma, and remains a major unmet need [5, 6]. Severe asthma accounts for only 5–10% of all cases, but it is responsible for the majority of direct and indirect costs. Thus, severe asthma poses a significant health care burden accounting for up to 50% of the asthma budget in developed and developing Countries.

Several multicenter cohort studies of patients with severe asthma have been published [7–10]. These studies

shed light upon some of the emerging clinical characteristics of this challenging group of patients and provide important insights into the strategic priorities for its management. Managing patients with severe asthma is complex, and requires a multidisciplinary approach and a standardized protocol, in addition to a uniform definition. Asthma is a rare cause of mortality, contributing to less than 1% of all deaths in most countries worldwide. Rates of death rise almost exponentially from mid-childhood to older ages, so the majority of asthma deaths occur after middle age [11]. Although asthma mortality trends declined in many high-income countries, studies have suggested that avoidable factors still play a major role in preventing severe asthma or asthma deaths. There is increasing evidence that severe asthma phenotypes are related to genetic factors, age of onset, disease duration, exacerbations, rhinosinusal disease and inflammatory characteristics [12–15]. For instance, in a study in a general population, as part of the European Community Respiratory Health Survey (ECRHS), there was no gender difference in asthma severity in the two surveys. However, those studies suggested that asthma severity might be less stable in women than in men [16]. Occupational exposures have also been associated with late-onset, and more severe asthma [17].

The evidence for a favorable clinical response to environmental control in severe asthma remains so far inconsistent. Atopy and allergy have long been

* Correspondence: carlo.lombardi@poliambulanza.it

¹Departmental Unit of Allergology- Clinical Immunology, and Respiratory Diseases, Fondazione Poliambulanza, Via Bissolati, 57, Brescia, Italy
Full list of author information is available at the end of the article

associated with asthma and, to some degree, with severe asthma. (Table 1) [7–10]. It is known that early-life exposures and sensitization to various allergens, occur in children with severe asthma [18], and the association between allergy and asthma severity is stronger in children [19, 20]. In general, the association among specific IgE sensitization (skin prick test or serum IgE assay), exposure and symptoms usually help to identify the factors contributing to the severity of disease [21]. Some specific allergens, in particular cockroach [22] and *Alternaria* [23] have been associated with more severe forms of asthma, and asthma deaths have been associated with high fungal spore counts in the environment [24]. In parallel, sensitization to mold has been associated with increased asthma severity and intensive care admissions in adults [25]. Another relevant aspect of severe asthma with allergic sensitization is the relationship with thunderstorms (“thunderstorm asthma”). An increasing body of evidence confirmed the occurrence of asthma epidemics during thunderstorms in pollen seasons, in various geographical areas [26]. Patients without asthma symptoms, but affected by seasonal rhinitis can also experience severe asthma attacks, and there is a link between thunderstorm asthma and pollen sensitizations [27, 28]. Identifying the possibly related causal allergens is mandatory for an appropriate therapeutic strategy [29, 30], although the evidence supporting secondary prevention of asthma (allergen avoidance) is still weak [31, 32].

To assess the impact of allergenic sensitization on severe asthma, a search of current scientific literature was performed and the results were filtered to identify relevant articles or studies with data from well-designed clinical studies in human patients. A PubMed literature search was performed using the Boolean string severe asthma* [title/abstract] AND allergic sensitization [title/abstract] AND atopy [title/abstract].

Mold sensitization and severe asthma

Allergy is one of the major pathophysiological aspects of asthma requiring hospitalisation, and the concentration of IgE antibodies is relevant in severe allergic asthma, as happens for instance in exacerbations due to rhinovirus infections [33]. In principle, any allergen can cause severe asthma in sensitized patients. Among children admitted to hospital for acute exacerbations, more than 85% are allergic. Of note, allergen-carrying particles with a diameter ≤ 5 microns such as HDM, dog, cat dander and fungal spores (*Aspergillus*, *Penicillium*, *Alternaria*) can entry the lower airways, thus more likely to cause asthma. In this context, it is important to distinguish between sensitization to thermotolerant fungi which can colonise the airways (mainly *Aspergillus*, *Penicillium* and *Candida*) so providing a persistent allergenic stimulus in the absence of airborne exposure and non-thermotolerant allergens such as *Cladosporium* and *Alternaria* where allergenic effects are directly related to airborne content of the spores. The former are associated with lung damage, whereas the latter are more closely associated with epidemic thunderstorm episodes. Several studies have found that there is a correlation between the severity of allergic diseases and the proteolytic activity of *Alternaria* extracts [34]. Furthermore, a possible key role of sensitization to *Alternaria* species has been observed in thunderstorm related severe asthma [35, 36]. In the specific case *Alternaria*, the prerequisites for severe asthma epidemics associated with thunderstorms are: sensitization, current asthma, sudden large allergen exposure, thunderstorm with cold outflow occurring at a time and location during an allergen season, in which many asthmatics are outdoors, sudden release of large amounts of respirable allergenic fragments, particularly fungal spores such as *Alternaria* [35–38]. Mold sensitivity is usually associated with increased severity of

Table 1 Demography and atopic status data from three of most representative studies on severe asthma

	Enfumosa study	Tenor study	SARP Study
Study design/location	Cross-sectional European multicentre study (9 Countries)	U.S. Multicentre Observational study	Observational cross-sectional multicentre study (9 sites in U.S. and 1 site in U.K.)
Patients (N.) with severe asthma	163	2282 (48% OF TOTAL)	204
Age characteristics	Age range: 17-65 yrs	Mean age \pm SD : 38.9 \pm 20.92 yrs	Mean age \pm SD: 41 \pm 13 yrs
Sex	Sex ratio (F/M) : 4.4 / 1	Not reported ^f	Females: 64%
≥ 1 Positive skin prick test	58% (VS. 78% OF Controlled asthmatics)	-	71% (VS. 85% of mild and 87% of moderate asthma)
Mean total serum IgE	109 KU/L ⁻¹ , 95% CI: 85-139	106.6 IU/ml ^a	2.0 \pm 7.6 ^b
References	2	3	4

^aOverall, the TENOR study patients with severe asthma had elevated geometric mean IgE values compared with patients with moderate and mild asthma. IgE values for children and adolescents increased with asthma severity

^bTotal serum IgE (log)

^cOverall patients (mild/moderate/severe asthma): females : 2945 (62.2%); males : 1792 (37.8%)

asthma and hospital admission in adults, while in children is related to increased bronchial hyperactivity [39]. Asthma-related deaths are more frequent in young adults during spore peaking [26, 40]. Molds are an important causative agent of severe asthma as thus the term SAFS (Severe Asthma associated with Fungal Sensitization) has been coined to identify those patients with severe asthma, not-responsive to standard therapy [41]. The exact prevalence of mold sensitivity is not well defined, but it is believed to range between 13% and 78% in atopic patients [42, 43]. Several species of fungi are considered responsible for allergic sensitization, but the more relevant belong to the Ascomycetes family: *Alternaria*, *Aspergillus*, *Botrytis*, *Epicoccum*, *Fusarium* and *Penicillium* species [41]. Sensitization to *Alternaria* and *Cladosporium* species are more frequently associated with persistent and severe asthma [41].

Molds are both outdoor and indoor persistent allergens, although with seasonal variations, that depend on climatic factors (rain, humidity, temperature, air pollutants and wind). Indoor spores can derive from molds present outdoor, or from inside damp and moist walls in buildings. Rain is usually necessary for spores discharge in air, not also from outdoor, but even from house surfaces, especially during thunderstorms [44]. Each species of fungi presents several allergens, that can be structural components of the cell and/or derived from metabolic products [45]. Currently 30 allergens from *Aspergillus sp*, 16 from *Penicillium sp*, 10 from *Cladosporium sp* and 9 from *Alternaria sp* have been identified. Although there is some documented cross-reactivity among allergens [46, 47], also species-specific allergens, such as Asp 1 and Alt 1, have been characterized [46, 47]. Exposure to fungal allergens can cause severe asthma through 3 different mechanisms: a) inhalation of spores or hyphae, that act as allergens in patients sensitized; b) fungal colonization of airway, i.e. allergic bronchopulmonary aspergillosis (ABPA), associated to sensitization to fungal antigens; c) fungal colonization of districts different from respiratory tract (generally skin) in patients sensitized to involved fungi [33]. This wide spectrum of clinical entities in patients with sensitization to fungi is due to their potent antigenicity and immunomodulatory activities [48]. Immunopathogenesis is mediated by β -glucans and their receptor, dectin-1. In fact, after the recognition of β -glucans, dectin 1 on macrophages surface triggers the release and the production of several inflammatory mediators [49]. Recent findings suggest that the immune response to fungi directs T cell towards Th17 cells, through dendritic cells action. In the same studies the Authors demonstrated that induction of Th17 cells strictly correlates with severe allergic asthma, with possible steroid resistance [46]. Fungal proteases act as

allergens, and also as mediators of tissue injury, inducing production of IL-6 and IL-8, proinflammatory cytokines involved in exacerbations of asthma. Moreover, it has been demonstrated that the receptor activated by protease (PAR) type 2 is overexpressed in bronchial tissue from asthmatic patients, suggesting a potential increased vulnerability to fungi in these subjects [42]. In case of colonization of the airways a Th-2 hypersensitivity mechanism is involved. Disease is characterized by increased severity of asthma, increased IgE serum level, transient infiltrates in lungs, presence of IgG and IgE against molds [33, 42]. The most common fungi implicated in pulmonary colonization are from *Aspergillum* species, less frequently *Candida*, *Curvularia* and *Penicillium* species can be involved [50]. Asthma therapy in this case is associated with antifungal systemic treatment [42]. The third mechanism was firstly proposed in 1930 by Wise et al., who observed that patients with skin and/or nails fungal infection presented an increased asthma severity [51], and a significant correlation with sinusitis, rhinitis and urticaria associated to fungal colonization of skin. Supporting evidences to this hypothesis are derived from several trials in which patients affected by severe asthma and fungal skin infection had a relevant improvement in asthma control after itraconazole and fluconazole [52, 53]. Sensitization to Asp f 1 and/or Asp f 3 may be more indicative of allergic asthma. [54]. It was also observed that pediatric severe asthma with fungal sensitization was associated with more oral steroid therapy and higher IL-33 levels [55].

Pollen sensitization and severe asthma

The relationship occurring between pollen sensitization and asthma severity has been widely studied, and an abundant literature on this aspect is currently available [13, 33]. The IgE antibody profile for a broad spectrum of allergen molecules, exhaled nitric oxide (F_{Eno}) and bronchial responsiveness were assessed in asthma patients. Asthmatic patients showed more frequently sensitization to grass, tree, weed pollens, furry animals, mold, latex and foods of plant origin. Asthma prevalence was increased in patients with food-pollen-perennial sensitization. In this group of patients also F_{Eno} and bronchial responsiveness were increased with respect to groups of patients with sensitization only to pollen, or food or perennial [56]. Some evidence suggested that air pollution may interact with airborne allergens enhancing the risk of atopic sensitization and exacerbation of symptoms in sensitized subjects. These phenomena are supported by current in vitro and animal studies showing that the combined exposure to air pollutants and allergens may have a synergistic or additive effect on asthma and allergies [57]. Ragweed pollen sensitization induces asthma much more frequently than other

pollens [58]. Concerning *Olea* sensitization, the association between the presence of asthma and sensitization to *Olea* e 7 resulted statistically significant [59]. To date, among pollens, only grass, *Parietaria* (Wall Pellitory) and *Olea* pollen have been suggested as possible triggers in thunderstorm-related asthma [60]. A thunderstorm-related asthma episode was observed in Naples (Italy) on June 2004, when six adults and one child received emergency treatment. All patients showed allergic respiratory symptoms upon exposure to *Parietaria* pollen but they were not sensitized to grasses [61]. Losappio et al. observed 20 patients with allergic sensitization to *Olea* pollen brought to an emergency department in Barletta, Italy, for sudden and severe asthmatic symptoms in May 2010 following a violent thunderstorm [36]. On the basis of these observations, all subjects affected by pollen allergy should be alerted to the danger of being outdoors during a thunderstorm in the pollen season, as such events may be an important cause of severe asthma exacerbations.

Animal dander sensitization and severe asthma

Pet allergy is considered one of the most important causes of severe or uncontrolled asthma. A specific IgE response to more than three animal-derived components was observed to be more common among uncontrolled severe asthmatics children compared to those with controlled asthma [62]. Component Resolved Diagnosis (CRD) allows the identification of specific allergens associated with the severity of asthma and the identification of cross reactive molecules that are clinically significant as well as Can f 6 or Fel d 4. They are lipocalin allergens and could explain the role in cross reactivity of dog with cat and horse. The physician can advise on whether or not to keep a household pet or which species could be tolerated. This may have a huge impact on the child's well-being [63]. CRD allows to evaluate the pattern of sensitization to pet IgE components and its association with clinical symptoms and their severity. Specific IgE to Can f 2 was significantly associated with asthma diagnosis, Can f 3 with moderate/severe rhinitis and asthma diagnosis, Can f 5 with persistent and moderate-severe rhinitis, and Equ c 3 with persistent rhinitis and severe asthma [64]. Furthermore, the sensitization to Can f 2 and Equ c 1 was more common in severe asthma than in children with controlled asthma [65]. Asthmatic children with cat allergy have higher Fel d 1-specific IgE levels as compared to those with rhinitis alone, and this suggests that high IgE levels to Fel d 1 could be a marker of increased asthma risk [66]. Fel d 2 is a serum albumin, abundant in saliva and dander. It is a highly cross-reactive molecule, associated with cat – pork syndrome but only a small number (10-

20%) of patients sensitized to Fel d 2 report immediate reactions to beef, whereas sensitization to Fel d 2 is associated with more severe respiratory symptoms [67].

Cockroach allergens sensitization and severe asthma

Cockroach allergy is recognized as an important cause of asthma and cockroach-induced asthma was described as a more severe disease, associated with perennial symptoms and high levels of total IgE. Cockroaches produce several allergens that induce sensitization, and exposure to high levels of cockroach allergens at home is a major risk factor for symptoms in sensitized individuals [68]. Recent data suggest that cockroach allergen may be a most relevant urban allergen exposure and may be related to asthma severity [69]. Indoor allergen exposure in inner-city areas has been of particular interest given that patients living in urban areas have increased asthma severity, decreased asthma control, and greater health care use [70]. Rosenstreich et al. found that cockroach allergens are easily detectable in inner-city homes [22]. Furthermore, this study demonstrated that asthmatic children sensitized and exposed to high levels of cockroach allergens had an increased asthma morbidity. Ahluwalia et al. observed that in an inner-city community with high exposure to cockroach allergens, there was a more strongly and consistent association with poor asthma outcomes [71]. Gelber et al. and Call et al. showed that cockroach sensitization was more common in asthmatics compared to non-asthmatics referred to an emergency room. When sensitization was associated with direct exposure, a very high association with asthma occurred. [72, 73]. In a study carried out in Thailand, the possible changes in disease severity and allergen sensitization of children with asthma in an interim period of 5 years was evaluated [74]. During the years 2004-2009, asthma severity increased with increasing sensitization to mite and mite plus cockroach. In another study conducted in a population of elderly urban patients with asthma, the presence of cockroach-specific serum IgE was associated with more severe asthma, as reflected by an increase in airway obstruction and hyperinflation [75]. In a Polish study it was observed that the concentration of Bla g 2 in houses was higher than previously reported in other European countries, and children with cockroach hypersensitivity had more often severe asthma than children with other allergies [76]. Previously identified allergens from *Blattella germanica* and *Periplaneta americana* (the most important domestic species), include Bla g 2 (inactive aspartic protease), Bla g 4 (calycin), Bla g 5 (glutathione-S-transferase), Bla g 6 (troponin), the Group 1 cross-reactive allergens Bla g 1 and Per a 1, Per a 3 (arylphorin), and Per a 7 (tropomyosin). On the basis of

this finding, we suggested that community-based asthma intervention strategies should prioritize reducing cockroach allergen exposure.

Sensitization to food allergens and severe asthma

Workers handling food products and derivatives are at increased risk of developing occupational asthma. Exposure to food allergens occurs primarily through inhalation of dust, steam, vapors and aerosolized proteins generated during the processing of foods. Most of the inhaled food allergies are IgE mediated, but objective evidence of asthma by monitoring peak expiratory flows during and off work or specific inhalation challenges usually provide a reliable diagnostic value [77]. Wheat may induce the well known baker's asthma: albumins and globulins (LTP, Tri a 14, alfa amylase inhibitor) are more involved than gluten (low – molecular – weight – glutenins, alfa, gamma omega 5 gliadin) [78]. Heat proteolytic resistant food allergens such as seafood (fish and shellfish), plants (LTP), spices, milk (casein), eggs (lysozyme, ovomucoid) and mushrooms can cause severe asthma attacks through inhalation [78, 79].

Conclusions

Severe asthma remains a major health concern, due to its relevant social costs. Despite these critical aspects, there are still many unmet needs with regard in particular the interpretation and comparison of the various studies carried out; for example, the different definitions of "severe asthma" adopted in the most important studies published so far (ENFUMOSA, SARP, TENOR, etc.) [3–8]. Different clinical and biological phenotypes of asthma are currently identified. Allergic asthma, with the atopic sensitization and the TH2 driven inflammation is the most frequent and the better known form of asthma [80]. Among the allergens that may cause asthma, some results to be more frequently associated to severe forms: molds, cockroach, pet dander, inhaled food-derived allergens. Also, "thunderstorm asthma" is frequently associated with severe symptoms due to a massive and sudden exposure to inhalant allergens. Thus, a detailed knowledge about the relevant allergens and causative factors is essential to properly diagnose, prevent, and treat the most severe forms of asthma.

There is evidence from some randomized controlled studies that ABPA treatment with systemic antifungal therapy can offer a therapeutic benefit to about 60% of patients [81].

Allergen immunotherapy (AIT) represents a valuable therapeutic option. A study of sublingual immunotherapy to *Dermatophagoides* in patients with allergic rhinitis with or without mild intermittent asthma showed an improved bronchial threshold to allergen challenge [29]. Another recent double-blind, randomized, placebo-

controlled trial, conducted in 109 European trial sites and including 834 adults with HDM allergy-related asthma not well controlled by ICS or combination products, and with HDM allergy-related rhinitis, demonstrated that the addition of HDM SLIT tablets increased the time to first exacerbation during ICS reduction, with an estimated absolute reduction at 6 months of 9 to 10 percentage points; the reduction was primarily due to an effect on moderate exacerbations [30]. Further studies of these approaches are required in severe asthma. An alternative and clinically proven approach for atopic severe asthma is the use of the monoclonal antibody to IgE (omalizumab), which reduces circulating IgE and leads to down-regulation of its high affinity receptor FcεR1 on mast cells and basophils [31]. Different promising therapeutic options are also currently in development and undergoing clinical trials for the treatment of severe asthma, including anti-interleukin agents (mepolizumab, benralizumab, reslizumab, dupilumab, brodalumab, lebrikizumab) [32].

Acknowledgements

Not applicable.

Funding

The Authors declare that they have received no funding for the realization of this manuscript.

Availability of data and materials

Not applicable.

Authors' contributions

Each author was responsible for the clinical work, collection and analysis of data and drafting the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

¹Departmental Unit of Allergology- Clinical Immunology, and Respiratory Diseases, Fondazione Poliambulanza, Via Bissolati, 57, Brescia, Italy. ²Departmental Unit of Allergology, AUSL of Piacenza, "Guglielmo da Saliceto" Hospital, Piacenza, Italy. ³Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy. ⁴Allergy and Respiratory Diseases, IRCCS San Martino-IST-University of Genoa, Genoa, Italy.

Received: 2 August 2016 Accepted: 15 December 2016

Published online: 06 January 2017

References

- Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: Phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax*. 2007;62:758–66.
- Sembajwe G, Cifuentes M, Tak SW, et al. National income, self-reported wheezing and asthma diagnosis from the World Health Survey. *Eur Respir J*. 2010;35:279–86.
- Gibson GJ, Loddiken R, Lundbaek B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. *Eur Respir J*. 2013;42:559–63.

4. W.A.A. The 2016 update of the Global Strategy for Asthma Management and Prevention; <http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/>
5. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. *J Allergy Clin Immunol*. 2010;126:926–38.
6. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43:343–73.
7. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. *Eur Respir J*. 2003;22:470–7.
8. Dolan CM, Fraher KE, Bleecker ER, TENOR Study Group, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. *Ann Allergy Asthma Immunol*. 2004;92(1):32–9.
9. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *J Allergy Clin Immunol*. 2007;119:405–13.
10. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM, British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. *Thorax*. 2010;65(9):787–94.
11. Sidebotham HJ, Roche WR. Asthma deaths; persistent and preventable mortality. *Histopathology*. 2003;43:105–17.
12. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. *Am J Respir Crit Care Med*. 2008;178:218–24.
13. Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. *J Allergy Clin Immunol*. 2011;127:382–9.
14. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. *J Allergy Clin Immunol*. 2004;113:101–8.
15. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genome-wide association study of asthma. *N Engl J Med*. 2010;363:1211–21.
16. Raheerison C, Janson C, Jarvis D, Burney P, Cazzoletti L, et al. Evolution of asthma severity in a cohort of young adults: is there any gender difference? *PLoS ONE*. 2009;4(9):e7146. doi:10.1371/journal.pone.0007146.
17. Henneberger PK, Mirabelli MC, Kogevinas M, et al. The occupational contribution to severe exacerbation of asthma. *Eur Respir J*. 2010;36:743–50.
18. Friedman MS, Powell KE, Hutwagner L, et al. Impact of changes in transportation and commuting behaviors during the 1996 Summer Olympic Games in Atlanta on air quality and childhood asthma. *JAMA*. 2001;285:897–905.
19. Fitzpatrick AM, Gaston BM, Erzurum SC, et al. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. *J Allergy Clin Immunol*. 2006;118:1218–1225.135.
20. Bossley CJ, Saglani S, Kavanagh C, et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. *Eur Respir J*. 2009;34:1052–9.
21. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. *N Engl J Med*. 2004;351:1068–80.
22. Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. *N Engl J Med*. 1997;336(19):1356–63.
23. O'Hollaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. *N Engl J Med*. 1991;324(6):359–63.
24. Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from asthma during the pollen season. *J Allergy Clin Immunol*. 1995;95(5, Pt. 1):955–61.
25. Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. *Allergy*. 2000;55(5):501–4.
26. D'Amato G, Vitale C, D'Amato M, Cecchi L, Liccardi G, Molino A, Vatrella A, Sanduzzi A, Maesano C, Annesi-Maesano I. Thunderstorm-related asthma: what happens and why. *Clin Exp Allergy*. 2016;46:390–6.
27. Venables KM, Allitt U, Collier CG, et al. Thunderstorm-related asthma – epidemic 24/25 June 1994. *Clin Exp Allergy*. 1997;27:725–36.
28. Nasser SM, Pulimood TB. Allergens and thunderstorm asthma. *Curr Allergy Asthma Rep*. 2009;9:384–90.
29. Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. *J Allergy Clin Immunol*. 2011;127(4):974–981, e1–e7.
30. Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma. a randomized clinical trial. *JAMA*. 2016;315(16):1715–25.
31. Siddiqui S, Gonen S, Wardlaw AJ. Advances in the Management of Severe Asthma. *Semin Respir Crit Care Med*. 2012;33(6):666–84.
32. McIvor RA. Emerging therapeutic options for the treatment of patients with symptomatic asthma. *Ann Allergy Asthma Immunol*. 2015;115:265–71.
33. Kennedy JL, Heymann PW, Platts-Mills TAE. The role of allergy in severe asthma. *Clin Exp Allergy*. 2012;42(5):659–69.
34. Snelgrove RJ, Gregory LG, Peiró P, Akthar S, Campbell GA, Walker SA, Lloyd CM. *Alternaria*-derived serine protease activity drives IL-33-mediated asthma exacerbations. *J Allergy Clin Immunol*. 2014;134(3):583–92.
35. Pulimood TB, Corden JM, Bryden C, et al. Epidemic asthma and the role of the fungal mold *Alternaria alternata*. *J Allergy Clin Immunol*. 2007;120:610–7.
36. Losappio L, Heffler E, Contento F, Cannito C, Rolla G. Thunderstorm-related asthma epidemic owing to *Olea europaea* pollen sensitization. *Allergy*. 2011;66:1510–1.
37. Grinn-Gofrøn A, Strzelczak A. Changes in concentration of *Alternaria* and *Cladosporium* spores during summer storms. *Int J Biometeorol*. 2013;57:759–68.
38. Matsuwaki Y, Wada K, White T, Moriyama H, Kita H. *Alternaria* fungus induces the production of GM-CSF, interleukin-6 and interleukin-8 and calcium signaling in human airway epithelium through protease-activated receptor 2. *Int Arch Allergy Immunol*. 2012;158:19–29.
39. O'Driscoll BR, Hipkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. *BMC Pulmonary Med*. 2005;5:4.
40. Khot A, Burn R. Seasonal variation and time trends of deaths from asthma in England and Wales 1960–82. *Br Med J (Clin Res Ed)*. 1984;289:233–4.
41. Agarwal R, Nath A, Aggarwal AN, Gupta D, Chakrabarti A. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India. *Mycoses*. 2010;53:138–43.
42. Arbes Jr SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. *J Allergy Clin Immunol*. 2005;116:377–83.
43. Bartra J, Belmonte J, Torres-Rodriguez JM, Cistero-Bahima A. Sensitization to *Alternaria* in patients with respiratory allergy. *Front Biosci*. 2009;14:3372–9.
44. Elbert W, Taylor PE, Andreae MO, Poschl U. Contribution of fungi to primary biogenic aerosols in the atmosphere: wet and dry discharged spores, carbohydrates, and inorganic ions. *AtmosChem Phys*. 2007;7:4569–88.
45. Achatz G, Oberkofler H, Lechenauer E, Simon B, Unger A, Kandler D, et al. Molecular cloning of major and minor allergens of *Alternaria alternata* and *Cladosporium herbarum*. *Mol Immunol*. 1995;32:213–27.
46. Tang RB, Chen YS, Chou H, Lee SS, Tai HY, Shen HD. cDNA cloning and immunologic characterization of a novel EF-1beta allergen from *Penicillium citrinum*. *Allergy*. 2005;60:366–71.
47. Kurup VP, Banerjee B, Hemmann S, Greenberger PA, Blaser K, Cramer R. Selected recombinant *Aspergillus fumigatus* allergens bind specifically to IgE in ABPA. *Clin Exp Allergy*. 2000;30:988–9.
48. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy*. 2013;43:850–73.
49. Zhang A, Biagini Myers JM, Brandt EB, et al. b-Glucan exacerbates allergic asthma independent of fungal sensitization and promotes steroid-resistant TH2/TH17 responses. *J Allergy Clin Immunol*. 2016. doi: 10.1016/j.jaci.2016.02.031. in press.
50. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. *J Allergy Clin Immunol*. 2012;129:2.
51. Wise F, Salzberger MB. Urticaria and hay fever due to *Trichophyton* (Epidermophyton interdigital). *JAMA*. 1930;95:1504–8.

52. Platts-Mills TA, Fiocco GP, Hayden ML, et al. Serum IgE antibodies to Thrichophyton in patients with urticaria, angioedema, asthma, and rhinitis: development of a radioallergosorbent test. *J Allergy Clin Immunol.* 1978;79:40–5.
53. Matsuoka H, Niimi A, Matsumoto A, et al. Specific IgE response to trichophyton and asthma severity. *Chest.* 2009;135:898–903.
54. Casaulta C, Fluckiger S, Cramer R, Blaser K, Schoeni MH. Time course of antibody response to recombinant *Aspergillus fumigatus* antigens in cystic fibrosis with and without ABPA. *Pediatr Allergy Immunol.* 2005;16:217–25.
55. Castanhinha S, Sherburn R, Walker S, et al. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. *J Allergy Clin Immunol.* 2015;136:312–22.
56. Patelis A, Gunnbjornsdottir M, Malinovschi A, Matsson P, Onell A, Hogman M, Alving K, Janson C. Population-based study of multiplex IgE sensitization in relation to asthma, exhaled nitric oxide, and bronchial responsiveness. *J Allergy Clin Immunol.* 2012;1(30):397–402.
57. Baldacci S, Maio S, Cerrai S, Sarno G, Baiz N, Simoni M, Annesi-Maesano I, Viegi G, HEALS Study. Allergy and asthma: Effects of the exposure to particulate matter and biological allergens. *Respir Med.* 2015;109(9):1089–104.
58. Wopfner N, Gadermaier G, Egger M, Asero R, Ebner C, Ferreira F. The spectrum of allergens in Ragweed and Mugwort Pollen. *Int Arch Allergy Immunol.* 2005;138:337–46.
59. Barber D, de la Torre F, Feo F, Florido F, Guardia P, Moreno C, Quiralte J, Lombardero M, Villalba M, Salcedo G, Rodríguez R. Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. *Allergy.* 2008;63(11):1550–8.
60. D'Amato G, Cecchi L, Liccardi G. Thunderstorm-related asthma: not only grass pollen and spores. *J Allergy Clin Immunol.* 2008;121:537–8.
61. D'Amato G, Ruffilli A, Ortolani C. Allergenic significance of *Parietaria* (pellitory-of-the-wall) pollen. In: D'Amato G, Spieksma F, Bonini S, editors. *Allergenic pollen and pollinosis in Europe.* Oxford: Blackwell Scientific Publications; 1991. p. 113–8.
62. Nordlund B, Konradsen JR, Kull I, Borres MP, Önell A, Hedlin G, Grönlund H. IgE antibodies to animal-derived lipocalin, kallikrein and secretoglobulin are markers of bronchial inflammation in severe childhood asthma. *Allergy.* 2001;67(5):661–9.
63. Konradsen JR, Fujisawa T, Hedlin G, Hilger C, Kleine-Tebbe J, Matsui C, Graham Roberts G, Ronmark E, Platts-Mills TAE. Allergy to furry animals: new insights, diagnostic approaches, and challenges. *J Allergy Clin Immunol.* 2015;135:616–25.
64. Uriarte SA, Sastre J. Clinical relevance of molecular diagnosis in pet allergy. *Allergy.* 2016;71(7):1066–8.
65. Konradsen JR, Nordlund B, Onell A, Borres MP, Gronlund H, Hedlin G. Severe childhood asthma and allergy to furry animals: Refined assessment using molecular-based allergy diagnostics. *Pediatr Allergy Immunol.* 2014;25:187–92.
66. Gronlund H, Adedoyin J, Reininger R, Varga EM, Zach M, Fredriksson M. Higher immunoglobulin E antibody levels to recombinant Fel d 1 in cat-allergic children with asthma compared with rhinoconjunctivitis. *Clin Exp Allergy.* 2008;38:1275–81.
67. Asaraoj A, Hamsten C, Wadén K, Lupinek C, Andersson N, Kull I, Curin M, Anto J, Bousquet J, Valenta R, Wickman M, van Hage M. Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study. *J Allergy Clin Immunol.* 2016;137(3):813–21.
68. Arruda LK, Chapman MD. The role of cockroach allergens in asthma. *Curr Opin Pulm Med.* 2001;7(1):14–9.
69. Sheehan WJ, Phipatanakul W. Difficult to Control Asthma: Epidemiology and its Link with Environmental Factors. *Curr Opin Allergy Clin Immunol.* 2015;15(5):397–401.
70. Szefer SJ, Gergen PJ, Mitchell H, Morgan W. Achieving asthma control in the inner city: do the National Institutes of Health Asthma Guidelines really work? *J Allergy Clin Immunol.* 2010;125(3):521–6.
71. Ahluwalia SK, Peng RD, Breyse PN, et al. Mouse allergen is the major allergen of public health relevance in Baltimore City. *J Allergy Clin Immunol.* 2013;132(4):830.
72. Gelber LE, Seltzer LH, Bouzoukis JK, et al. Sensitization and exposure to indoor allergens as risk factors for asthma among patients presenting to hospital. *Am Rev Respir Dis.* 1993;147:573–8.
73. Call RS, Smith TF, Morris E, Chapman MD, Platts-Mills TAE. Risk factors for asthma in inner city children. *J Pediatr.* 1992;121:862–6.
74. Yuenyongviwat A, Koonrangsombon D, Sangsupawanich P. Recent 5-year trends of asthma severity and allergen sensitization among children in southern Thailand. *Asian Pac J Allergy Immunol.* 2013;31:242–6.
75. Rogers L, Cassino C, Berger KI, Goldring RM, Norman RG, Klugh T, Reibman J. Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers. *Chest.* 2002;122(5):1580–6.
76. Stelmach I, Jerzynska J, Stelmach W, Majak P, Chew G, Gorski P, Kuna P. Cockroach allergy and exposure to cockroach allergen in Polish children with asthma. *Allergy.* 2002;57(8):701–5.
77. Cartier A. The role of inhalant food allergens in occupational asthma. *Curr Allergy Asthma Rep.* 2010;10:349–56.
78. Palacin A, Varela J, Quirce S, del Pozo V, Tordesillas L, Barranco P, Fernandez-Nieto M, Sastre J, Diaz-Perales A. Recombinant lipid transfer protein Tri a 14 : a novel heat and proteolytic resistant tool for the diagnosis of baker's asthma. *Clin Exp Allergy.* 2009;39:1267–76.
79. De Ferrari L, Chiappori A, Bagnasco D, Riccio AM, Passalacqua G, Canonica GW. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? *Expert Rev Respir Med.* 2016;10(1):29–38.
80. Stokes JR, Casale TB. Characterization of asthma endotypes: implications for therapy. *Ann Allergy Asthma Immunol.* 2016;117(2):121–5.
81. Denning DW, O'Driscoll BR, Hogaboam CM, et al. The link between fungi and severe asthma: a summary of the evidence. *Eur Respir J.* 2006;27:615–26.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

